Using Advanced Drug Development Technologies for Better Treatments Presented By Catalent Experts at ICSE/CPhI Japan 2012
Somerset, NJ – March 15, 2012 – Catalent Pharma Solutions, a leading global industry partner in product development, delivery and supply has extensive expertise in bringing more products to more markets around the world and will present a series of advanced solutions to the Japanese and Asian pharmaceutical industry at the International Contract Services Expo (ICSE)/CPhI being held in Tokyo, Japan on March 21-23, 2012. A team of Catalent experts will be presenting on topics such as solving bioavailability challenges, optimizing global presence, increasing speed to market, and improving the therapeutic profile and performance of treatments.
On Thursday, March 22 at 14:15 -5:15 (Room E, East Hall 5), Dr. Gregory T. Bleck, Senior Director of Research and Development, Catalent Biologics, will lead a BioPharma technical seminar , “Catalent Biologics GPEx® Technology: cDNA to Stable-High Expressing Mammalian Cell Line in Four Months and a 2-5 g/L Production Process in Six Months.” Attendees will learn how Catalent Biologics can help increase the speed of large molecule drug development to clinic by utilizing GPEx® mammalian cell line engineering technology and integrated biomanufacturing.
Additionally, three Catalent experts will be presenting at the ICSE Japan exhibitor showcase sessions. The presenters will elaborate on Catalent’s drug development and delivery options and explain how Catalent can help to enhance bioavailability , and improve therapeutic profiles and patient adherence. The ICSE Japan exhibitor showcase presentation schedule is as follows:
- Wednesday, March 21, 11:00-11:30 (Room A-01): Hironori Kubota, Director, Japan Business Development, Softgel Technologies, Catalent Pharma Solutions will present, “Solving bioavailability challenges for poorly water-soluble compounds with proven Softgel Technology.”
- Thursday, March 22, 16:00 -16:30 (Room: C-14): Yutaka Takeuchi, Business Account Director, Japan, Catalent Pharma Solutions will present, “Optimizing your global presence with tailored solutions from Catalent.”
- Friday, March 23, 13:00 13:30 (Room: A-17): Jorge S. Yamamoto, Director, Asia-Pacific Business Development, Zydis® & Modified Release Technologies, Catalent Pharma Solutions, will present “Improving the Performance of your Treatments with Zydis® Fast-Dissolve Technology .”
To schedule an interview with Catalent during ICSE/CPhI Japan, please contact Patricia McGee at email@example.com .
Catalent will also showcase its global reach and focus on the enhancement of many innovative drug development and delivery technologies and capabilities, highlighted by the recent completion of the acquisition of Aptuit’s clinical trials business solidifying Catalent as a global leader in clinical trial and drug development solutions, as well as the partnership to provide integrated biomanufacturing for Catalent’s proprietary Gene Product Expression Technology (GPEx®) with Toyobo Biologics, Inc. (TBI), a leading provider of biomanufacturing capabilities in Japan, and the recent expansion of its facilities in Aprilia, Italy, Swindon, UK and Schorndorf, Germany
For more information on Catalent at ICSE/CPhI Japan, click here .
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ.